mick
4年前
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
? FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
? DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
? KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
? TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types:
? ANTIVIRAL
? VAX
? ANTIBODY
? RNA
mick
4年前
$FUJIF Candidate: Favipiravir (marketed by Fujifilm as Avigan® and by Hisun in China as Favilavir)
Category: RNA, ANTIVIRAL
Type: Broad spectrum anti-viral agent that is designed to selectively and potently inhibit the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Japan has approved Avigan for novel or re-emergent influenza and was previously used to treat Ebola patients in Guinea.
Status: Appili Therapeutics said August 10 it was granted FDA clearance to expand its Phase II clinical trial (NCT04448119) into the U.S. to assess the safety and efficacy of favipiravir tablets in controlling outbreaks following exposure to COVID-19 in long-term care facilities. Appili said it intends to enroll up to 760 participants in the trial across both the U.S. and in Canada. Health Canada provided regulatory clearance on May 21 for the Phase II study, designed to evaluate Fujifilm Toyama Chemical’s favipiravir as a preventative measure against COVID-19 outbreaks.
Russia and India have approved Favipiravir-based antiviral medications for emergency treatment of COVID-19, with additional trials of the antiviral drug in COVID-19 being conducted in countries that include the U.S., Japan, China, and the U.K.
Fujifilm said April 15 it has expanded the manufacturing capacity of Fujifilm Toyama Chemical to increase production of Avigan® tablets. The company expects to progressively increase its monthly production of Avigan up to 100,000 treatment courses by July—2.5 times as much as March—and up to 300,000 treatment courses by September.
Earlier in April, Fujifilm launched its first U.S. clincal trial for Avigan in Massachusetts, where it is assessing the drug on approximately 50 COVID-19 patients at Brigham and Women’s Hospital, Massachusetts General Hospital, and the University of Massachusetts Medical School.
Japan’s Prime Minister Shinzo Abe told reporters in March that his government will partner with other countries to launch trials of on COVID-19 patients and ramp up its production, with plans to pursue approval if it succeeds in clinical trials now underway at Fujita Health University Hospital in Aichi Prefecture and other institutions, according to NHK. Japan’s government plans to stockpile 2 million treatment courses of Avigan as part of its emergency economic package, announced April 7.
Zhang Xinmin, an official at China’s Science and Technology Ministry, told reporters March 17 that favipiravir produced positive results in clinical trials in Wuhan and Shenzhen involving 340 patients—including a shortening of the time after treatment that patients tested negative for COVID-19 from 11 days to four, and improved lung conditions in 91% of treated patients vs. 62% of untreated patients, as measured via x-rays. Fujifilm has responded with a statement stressing that Avigan remained under study and had not been approved.
China’s stance contrasts with that of South Korea, where the Ministry of Food and Drug Safety has opted not to import Avigan for COVID-19, after a team of infectious disease experts concluded there was not enough clinical data to prove the drug’s efficacy. Citing unnamed sources, Politico reported March 31 that President Donald Trump’s administration sought FDA emertgency use authorization for Avigan following a conversation with Abe, and that the U.S. Department of Health and Human Services would not comment since it involved pre-decisional activity.
Japan’s Health Minister Katsunobu Kato said his ministry would recommend Avigan, developed by Fujifilm-owned Toyama Chemical, for use as a coronavirus treatment after test dosages appeared effective in mild and asymptomatic cases at least two medical institutions. In China, the National Health Commission approved Hisun’s version of the drug as an investigational treatment for SARS-CoV-2. Fujifilm granted Hisun a license in 2016 to use its Favipiravir-related patents in China to develop, manufacture and market an anti-influenza drug.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
? FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
? DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
? KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
? TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types:
? ANTIVIRAL
? VAX
? ANTIBODY
? RNA
Goodbuddy4863
5年前
$$ FUJIF **
This is My Gift to all My Friends that I have made while being on IHUB:
Fujifilm up almost $12 Bucks today[posted Late wednesday night].
Drug being used to treat flu in Japan is 'clearly effective' in treating coronavirus, Chinese officials claim:
https://www.dailymail.co.uk/news/article-8125513/Drug-used-treat-flu-Japan-clearly-effective-Chinese-officials-say.html?ito=social-facebook&fbclid=IwAR0Kisa_B1K4osC0vtFOyjw90LNF_RfqBc_tT0anx8QKrLJc-L3wEm7TJAc
flu drug is 'clearly effective' in treating coronavirus, medical experts in China have claimed.
Favipiravir, the active ingredient in a Japanese anti-flu medicine called Avigan, was trialled on 340 patients with the killer disease in China.
Patients who took Favipiravir recovered quicker and showed greater lung improvement compared with patients not given the drug.
Anti-influenza Avigan tablets, produced by Japan's Fujifilm, are displayed in Tokyo on October 22, 2014. Individuals given Favipiravir in Shenzhen gave negative results around four days after testing positive, compared to an average of 11 days for those not administered the drug, according to Japanese media +3
Anti-influenza Avigan tablets, produced by Japan's Fujifilm, are displayed in Tokyo on October 22, 2014. Individuals given Favipiravir in Shenzhen gave negative results around four days after testing positive, compared to an average of 11 days for those not administered the drug, according to Japanese media
The component is thought to block the virus from replicating in the body.
Doses will be investigated in more COVID-19 patients by Hong Kong researchers, who claim they will give their pill 'for free' if studies show it is safe.
However, contradictory clinical trials suggest Favipiravir will not be useful in patients who have more severe illness.
As of yet, there isn't a treatment for the new coronavirus causing a global pandemic. Most people have mild symptoms and can recover at home within a week.
Almost 200,000 have been infected and 7,9000 have died.
Avipiravir is an active ingredient which has shown to be effective against flu strains, yellow fever, foot-and-mouth-disease and some other virus families.
It was given to 80 patients in Shenzen and in Wuhan, where the novel coronavirus first emerged in December 2019.
Favipiravir has been effective, with no obvious side-effects, in helping coronavirus patients recover, Zhang Xinmin, an official at China's Science and Technology Ministry, told reporters at a news conference on Tuesday.
A worker wearing protective suit checks the body temperature of an employee at the entrance of OrbusNeich Medical (Shenzhen) Co. Ltd amid the coronavirus outbreak on March 6, 2020 in Shenzhen, Guangdong Province of China. Trials of the Avigan anti-influenza drug in Shenzhen proved successful in reducing the duration of the disease in patients, according to Chinese officials +3
A worker wearing protective suit checks the body temperature of an employee at the entrance of OrbusNeich Medical (Shenzhen) Co. Ltd amid the coronavirus outbreak on March 6, 2020 in Shenzhen, Guangdong Province of China. Trials of the Avigan anti-influenza drug in Shenzhen proved successful in reducing the duration of the disease in patients, according to Chinese officials
'It has a high degree of safety and is clearly effective in treatment,' Mr Xinmin said, according to The Guardian.
Patients who were given the medicine in Shenzhen had negative results for the coronavirus an average of four days after being diagnosed, meaning there was no trace of the virus in their body.
This compared with 11 days for those who were not treated with the drug, according to local media.
X-rays showed improvements in lung condition in nine in ten of the patients who were treated with Favipiravir, compared to six in ten of those without the drug.
It is not clear what the results were in patients in Wuhan.
It's also unknown which branded Favipiravir drug the patients were given.
One of the most known is Avigan, manufactured by a subsidiary of Fujifilm, which is better known for its cameras. The drug was approved for use in Japan in 2014 as a new flu treatment.
Fujifilm Toyama Chemical, the medical arm of Fujifilm – has declined to comment on the clinical trial, The Guardian reports.
Goodbuddy4863
5年前
Fujifilm up almost $12 Bucks today
Drug being used to treat flu in Japan is 'clearly effective' in treating coronavirus, Chinese officials claim:
https://www.dailymail.co.uk/news/article-8125513/Drug-used-treat-flu-Japan-clearly-effective-Chinese-officials-say.html?ito=social-facebook&fbclid=IwAR0Kisa_B1K4osC0vtFOyjw90LNF_RfqBc_tT0anx8QKrLJc-L3wEm7TJAc
flu drug is 'clearly effective' in treating coronavirus, medical experts in China have claimed.
Favipiravir, the active ingredient in a Japanese anti-flu medicine called Avigan, was trialled on 340 patients with the killer disease in China.
Patients who took Favipiravir recovered quicker and showed greater lung improvement compared with patients not given the drug.
Anti-influenza Avigan tablets, produced by Japan's Fujifilm, are displayed in Tokyo on October 22, 2014. Individuals given Favipiravir in Shenzhen gave negative results around four days after testing positive, compared to an average of 11 days for those not administered the drug, according to Japanese media +3
Anti-influenza Avigan tablets, produced by Japan's Fujifilm, are displayed in Tokyo on October 22, 2014. Individuals given Favipiravir in Shenzhen gave negative results around four days after testing positive, compared to an average of 11 days for those not administered the drug, according to Japanese media
The component is thought to block the virus from replicating in the body.
Doses will be investigated in more COVID-19 patients by Hong Kong researchers, who claim they will give their pill 'for free' if studies show it is safe.
However, contradictory clinical trials suggest Favipiravir will not be useful in patients who have more severe illness.
As of yet, there isn't a treatment for the new coronavirus causing a global pandemic. Most people have mild symptoms and can recover at home within a week.
Almost 200,000 have been infected and 7,9000 have died.
Avipiravir is an active ingredient which has shown to be effective against flu strains, yellow fever, foot-and-mouth-disease and some other virus families.
It was given to 80 patients in Shenzen and in Wuhan, where the novel coronavirus first emerged in December 2019.
Favipiravir has been effective, with no obvious side-effects, in helping coronavirus patients recover, Zhang Xinmin, an official at China's Science and Technology Ministry, told reporters at a news conference on Tuesday.
A worker wearing protective suit checks the body temperature of an employee at the entrance of OrbusNeich Medical (Shenzhen) Co. Ltd amid the coronavirus outbreak on March 6, 2020 in Shenzhen, Guangdong Province of China. Trials of the Avigan anti-influenza drug in Shenzhen proved successful in reducing the duration of the disease in patients, according to Chinese officials +3
A worker wearing protective suit checks the body temperature of an employee at the entrance of OrbusNeich Medical (Shenzhen) Co. Ltd amid the coronavirus outbreak on March 6, 2020 in Shenzhen, Guangdong Province of China. Trials of the Avigan anti-influenza drug in Shenzhen proved successful in reducing the duration of the disease in patients, according to Chinese officials
'It has a high degree of safety and is clearly effective in treatment,' Mr Xinmin said, according to The Guardian.
Patients who were given the medicine in Shenzhen had negative results for the coronavirus an average of four days after being diagnosed, meaning there was no trace of the virus in their body.
This compared with 11 days for those who were not treated with the drug, according to local media.
X-rays showed improvements in lung condition in nine in ten of the patients who were treated with Favipiravir, compared to six in ten of those without the drug.
It is not clear what the results were in patients in Wuhan.
It's also unknown which branded Favipiravir drug the patients were given.
One of the most known is Avigan, manufactured by a subsidiary of Fujifilm, which is better known for its cameras. The drug was approved for use in Japan in 2014 as a new flu treatment.
Fujifilm Toyama Chemical, the medical arm of Fujifilm – has declined to comment on the clinical trial, The Guardian reports.
FUJIF)
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Golden Cross
4年前
